Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Ocumension Therapeutics
  6. News
  7. Summary
    1477   KYG674111011

OCUMENSION THERAPEUTICS

(1477)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Ocumension Therapeutics Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2021

09/20/2021 | 04:45am EDT

Ocumension Therapeutics reported unaudited consolidated earnings results for the six months ended June 30, 2021. For the six months, the company announced revenue of RMB 20,803,000 compared to RMB 1,952,000 a year ago. Loss for the period was RMB 69,609,000 compared to RMB 1,741,770,000 a year ago. Basic and diluted loss per share was RMB 0.12 compared to RMB 27 a year ago.


ę S&P Capital IQ 2021
All news about OCUMENSION THERAPEUTICS
10/12OCUMENSION THERAPEUTICS : China Approves Clinical Trial of Ocumension Therapeutics Drug fo..
MT
10/12Ocumension Therapeutics Announces Approval Received for Clinical Trial of Class I New D..
CI
09/20Ocumension Therapeutics Reports Unaudited Consolidated Earnings Results for the Six Mon..
CI
09/15OCUMENSION THERAPEUTICS' : Phase 3 Clinical Trial Application for Eye Inflammation Treatme..
MT
09/14Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical ..
CI
08/25OCUMENSION THERAPEUTICS : Snaps Up Interests In Two Eye Drugs In China From Novartis
MT
08/25OCUMENSION THERAPEUTICS : Acquires all the Equity Interests in Two Ophthalmic Products Mai..
PR
08/23OCUMENSION THERAPEUTICS : Unit Buying Chinese Licenses for Ocular Itch Treatment for $35 M..
MT
08/20Ocumension Therapeutics Announces Interim Earnings Results for the 6 Months Ended 30 Ju..
CI
08/20OCUMENSION THERAPEUTICS : Announces 2021 Interim Results
PR
More news
Financials
Sales 2021 81,1 M 12,6 M 12,6 M
Net income 2021 -438 M -68,1 M -68,1 M
Net cash 2021 1 655 M 257 M 257 M
P/E ratio 2021 -15,8x
Yield 2021 -
Capitalization 9 817 M 1 525 M 1 526 M
EV / Sales 2021 101x
EV / Sales 2022 35,9x
Nbr of Employees 187
Free-Float 43,5%
Chart OCUMENSION THERAPEUTICS
Duration : Period :
Ocumension Therapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OCUMENSION THERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 15,36 CNY
Average target price 27,05 CNY
Spread / Average Target 76,1%
EPS Revisions
Managers and Directors
Ye Liu Chief Executive Officer & Executive Director
Jian Ping Yang Finance Director
Lian Yong Chen Non-Executive Chairman
Chang Dong Liu Chief Scientific Officer
Dong Hong Chen Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
OCUMENSION THERAPEUTICS-31.26%1 525
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657